PCM
LRMR icon

Prelude Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Prelude Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.9K Hold
10,867
– – ﹤0.01% 1126
2025
Q4 		$41.4K Hold
10,867
– – ﹤0.01% 1245
2025
Q3 		$35.1K Hold
10,867
– – ﹤0.01% 1113
2025
Q2 		$31.4K Buy
+10,867
New +$25.2K ﹤0.01% 966
2023
Q3 		– Sell
-19,013
Closed -$59.5K – 1260
2023
Q2 		$59.5K Buy
19,013
+6,313
+50% +$25.8K ﹤0.01% 965
2023
Q1 		$57.5K Buy
+12,700
New +$66.4K ﹤0.01% 996
2018
Q2 		– Sell
-258
Closed -$23K – 1814
2018
Q1 		$23K Buy
+258
New +$21.9K ﹤0.01% 1237
2017
Q4 		– Sell
-108
Closed -$5K – 1563
2017
Q3 		$5K Buy
+108
New +$4.49K ﹤0.01% 1506
2017
Q2 		– Sell
-1,742
Closed -$97K – 1740
2017
Q1 		$97K Buy
1,742
+1,700
+4,048% +$84.4K 0.01% 792
2016
Q4 		$2K Sell
42
-58
-58% -$2.35K ﹤0.01% 1489
2016
Q3 		$4K Buy
+100
New +$4.54K ﹤0.01% 1499

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Prelude Capital Management's LRMR Position: Q1 2026 in Review

Prelude Capital Management held its Larimar Therapeutics (LRMR) position steady in Q1 2026 at 10,867 shares worth $48.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1126.

Prelude Capital Management first reported a position in LRMR in Q3 2016 and has held it in 11 quarters since. The position peaked at $97K in Q1 2017. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Prelude Capital Management held 10,867 shares of Larimar Therapeutics worth $48.9K as of Q1 2026.
  • Prelude Capital Management left its Larimar Therapeutics share count unchanged in Q1 2026.
  • Larimar Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1126 holding.
  • Prelude Capital Management first reported a position in Larimar Therapeutics in Q3 2016 and has held it in 11 quarters since.
  • Prelude Capital Management's Larimar Therapeutics position peaked at $97K in Q1 2017.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.